Ebb Complete Tamponade System (CTS-lOOO) 에 대한 현장 안전성 서한

Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI)에 따르면, 해당 현장 안전성 서한 는 Slovenia 에서 Clinical Innovations LLC 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

현장 안전성 서한은 의료기기 제조사 또는 제조사 대리인이 시중에 유통되고 있는 자사 의료기기 제품에 대하여 취할 수 있는 조치를 알리는 소통방식입니다. 주요 대상층은 보건의료업계 종사자와 의료기기 사용자들입니다. 여기에는 회수(recall) 조치와 경고도 포함될 수 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Field Safety Notice
  • 날짜
    2015-07-09
  • 사례 국가
  • 사례 출처
    AMPMDRS
  • 비고 / 경고
    Data from Slovenia is current through February 2019. All of the data comes from the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (via FOI), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Slovenia.
  • 데이터 추가 비고
  • 원인
    This is to inform you of a voluntary global recall of clinical innovations’ ebb complete tamponade system (cts- 1000) involving lot numbers 1214—v-424; 1214-f-403 .The purpose of the recall is to address the potential for a balloon leak which may affect your ability to deliver therapy, when needed. clinical innovations’ records indicate you have received a product that is affected by this action. following a report that an ebb complete tamponade system (cts-looo) had leaked during use, clinical innovations conducted an investigation on the returned device and concluded that the leakage was caused by a failure mode of the bond at distal end of the uterine balloon a balloon leak can be identified by a failure to arrest bleeding, ultrasound revealing loss of balloon volume, or blood-tinged liquid being expelled from the drainage tube. a uterine balloon with a leak may not provide the anticipated tamponade effect, requiring further intervention. although unlikely, death could occur due to the failure mode associated with this recall. in the report received, the patient had stabilized prior to the leak being noticed by the clinical team. because there is a potential for additional interventions with a balloon leak (such as arterial embolization or surgery) required to control a postpartum hemorrhage, we are requesting that you return all unused ebb complete tamponade system (cts-looo) from the above—listed lot numbers. no other clinical innovations products are affected by this issue.

Device

Manufacturer